Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...
CEO Mike Mahoney said during the company's morning earnings call that Boston Scientific has "elected to temporarily pause" a trial of its Farapulse device in patients with atrial fibrillation who ...
Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a few unanticipated observations”. The trial – which tests Boston ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback